Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

Anje Cauwels1,5*, Sandra Van Lint1, Elke Rogge1,5, Annick Verhee1, Bram Van Den Eeckhout3, Shengru Pang2, Marco Prinz2,4, Niko Kley5, Gilles Uzé3 & Jan Tavernier1,5

Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose escalation. In addition, the mechanism of action of IFN in MS is multifactorial and still not completely understood. Using AcTaferons (Activity-on-Target IFNs, AFNs), optimized IFN-based immunocytokines that allow cell-specific targeting, we have previously demonstrated that specific targeting of IFN activity to dendritic cells (DCs) can protect against experimental autoimmune encephalitis (EAE), inducing in vivo tolerogenic protective effects, evidenced by increased indoleamine-2,3-dioxygenase (IDO) and transforming growth factor β (TGFβ) release by plasmacytoid (p) DCs and improved immunosuppressive capacity of regulatory T and B cells. We here report that targeting type I IFN activity specifically towards B cells also provides strong protection against EAE, and that targeting pDCs using SiglecH-AFN can significantly add to this protective effect. The superior protection achieved by simultaneous targeting of both B lymphocytes and pDCs correlated with improved IL-10 responses in B cells and conventional cDCs, and with a previously unseen very robust IDO response in several cells, including all B and T lymphocytes, cDC1 and cDC2.

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS). It is caused by an immune-mediated attack on the axonal myelin sheath, leading to debilitating brain and spinal cord damage. What exactly triggers MS is not completely understood, and is probably the combined result of genetic predisposition, environmental and viral factors1. The majority of MS patients are women, who experience their first symptoms between the ages of 20 and 40. For about 85% of these patients, MS starts with relapsing–remitting (RR) short episodes of worsening functions. If untreated, about half of these RR-MS patients will transition to secondary progressive (SP) MS within a decade of diagnosis. Worldwide, more than 2 million people are suffering from MS, and the prevalence seems to increase with latitude1. There are, however, several exceptions to this equatorial-polar gradient, such as very low rates in Canadian Inuit, Scandinavian Lapps and New Zealand Maori, and remarkably high rates in Sardinians and Palestinians2,3.

First line RR-MS treatment consisted for a long time only of type I IFN (IFN) and Glatiramer Acetate. More recently, oral drugs (Fingolimod, Teriflunomide, Dimethyl Fumarate) have gained significant importance as disease modifying therapies (DMTs)1,4. However, their exact modes of action are incompletely understood, and side effects including itching, alopecia, digestive problems and liver toxicity are frequent. During recent years, we have also seen the approval of several very successful antibody treatments, mainly used as second-line DMTs. These include Natalizumab (anti-VLA4), Alemtuzumab (anti-CD52), Daclizumab (anti-CD25) and Ocrelizumab (anti-CD20). These antibody therapies usually display better and longer-lasting effectiveness1,4. However, they

---

1Cytokine Receptor Laboratory, VIB Medical Biotechnology Center, Ghent University, A. Baertsoenkaai 3, 9000 Ghent, Belgium. 2Institute of Neuropathology, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. 3CNRS UMR 5235, University Montpellier, 34095 Montpellier, France. 4BIOSS Centre for Biological Signalling Studies, University of Freiburg, 79106 Freiburg, Germany. 5Oronis Biosciences, 9052 Ghent, Belgium. *email: acauwels@orionisbio.com; jtavernier@orionisbio.com
also come with higher safety concerns, and Daclizumab was recently even withdrawn after reports of severe liver damage and inflammatory (meningo)encephalitis.

In general, B cell depletion, although originally excluded from being promising based on negative preclinical mouse models, seems to be correlated with the best protection. This may be achieved by anti-CD20 therapies such as Ocrelizumab, Rituximab or Ofatumumab, but also Alemtuzumab (anti-CD52) and the recently approved deoxyadenosine analog Cladribine/Mavenclad have been shown to efficiently deplete both B and T cells, followed by a rapid and selective repopulation with immature and mature B cells, while the disease-provoking memory B cells remain gone. In retrospect, also the efficacy of other successful therapies, including that of IFN, seems to be correlated with memory B cell depletion. Whether or not these new and promising B cell depletion strategies will be compromised by increased risks (inflammatory as well as oncologic) remains to be seen.

Another strategy that recently has gained interest is the treatment with autologous ex vivo generated tolerogenic dendritic cells (tolDC), not only for the treatment of MS, but also for other auto-immune diseases such as rheumatoid arthritis (RA), type 1 diabetes (T1D) and Crohn’s disease (CD). To generate these tolDCs, immunosuppressive agents are used to confer a tolerogenic phenotype to ex vivo generated DCs. These include vitamin D3, rapamycin, corticosteroids or immunosuppressive cytokines such interleukin-10 (IL-10) and TGFβ. Intriguingly, also pro-inflammatory cytokines may have the capacity to induce DC tolerance, such as IFN and TNF.

IFN was the very first DMT to be approved for MS. Despite more than 25 years of use, its exact mechanisms of action and cellular targets remain largely unknown. In addition, IFN treatment causes multiple side effects, including flu-like symptoms, leukopenia, liver damage and depression. Furthermore, up to 50% of MS patients are unresponsive to IFN, and in a subset of patients IFN treatment even induces relapses. One possible explanation for this could be a mixed cellular response, where IFN signaling in certain cell types has a protective disease delaying effect, while in other cell types it has a harmful disease amplifying effect. Indeed, we have recently shown significant protection against EAE development by specific delivery of IFN activity to dendritic cells (DCs), whereas delivery to CD8+ cells was rather detrimental. To cell specifically deliver IFN activity, we use AcTferons (AFNs), which consist of mutant type I IFN coupled to single domain antibodies (sdAbs) or ligands selectively recognizing cell specific surface markers.

In light of the recent successes reported with B cell depleting strategies in MS patients, in combination with the inability of IFN to dampen EAE progression in mice in the absence of B cells, we decided to compare targeting of IFN activity towards plasmacytoid DC (pDC) and/or conventional type 1 DC (cDC1) with B cell targeting. We found that B cell targeting can be superior to DC targeting, and that the specific combination of pDC and B cell targeting provides even better results than the individual treatments. This superior protection by type I IFN signaling in pDCs plus B lymphocytes is correlated with enhanced IL-10 expression in B cells and cDCs, as well as with IDO expression in all B and T lymphocytes and in type 1 and type 2 conventional DCs.

**Results**

Targeting IFN activity to B cells protects without toxicity. The active EAE model using C57BL/6 mice immunized with MOG35-55 peptide is very robust and uniform and widely employed for understanding disease pathology and validating potential novel treatments. In this model, we have previously shown good protection with DC-targeted AFNs, for which we used either Clec9A-AFN or SiglecH-AFN, the former being superior thanks to targeting of both pDCs and cDC1s. SiglecH, in contrast to Clec9A, is only present on pDCs in mice. In the current study, we treated EAE mice daily, starting on day 7 after MOG inoculation, with either PBS or 5000 IU of CD20-AFN, or 5000 IU Clec9A-AFN for comparison, and monitored clinical scores and body weight loss. Depending on the experiment, targeting B cells with CD20-AFN was consistently either as efficient (Fig. 1A–C), or sometimes even more efficient than DC-targeted AFN (Fig. 1D–F). Immunohistochemical analysis of spinal cords confirmed that CD20-AFN could better prevent neuronal damage and CNS inflammation compared to Clec9A-AFN (Fig. 1G–H).

Importantly, targeting B cells was not accompanied by the severe hematological deficits generally observed by high dose WT mIFN therapy, which we have previously shown to be mildly efficient to delay disease progression (Supplementary Figure). There is, however, a minor lymphopenia induced by CD20-AFN. This is due to a partial depletion of B lymphocytes by CD20-AFN therapy, as shown before.

Reducing the dose of AFN from 5000 to 1000 IU (Fig. 2A,C) or 100 IU (Fig. 2B,C) underscored the better effect of B cell targeting over DC targeting. In addition, 5000 IU of B cell targeted CD20-AFN also prevented disease progression when therapy was started after onset of disease, on day 12, just like DC targeting, but also in this therapeutic setting, B cell targeting was better than DC targeting (Fig. 2D–F). Indeed, CD20-AFN therapy led to a rapid increase in body weight, whereas DC-targeting dampened the body weight loss rather than reverting it (Fig. 2E). In addition, upon cessation of AFN therapy, CD20-AFN treated mice reverted to progressive disease less rapidly (Fig. 2D) and were less prone to develop severe paralysis (Fig. 2F).

Targeting IFN activity to both B cells and pDCs results in superior protection. As we already published recently, the DC type that needs to be primarily stimulated to prevent disease progression are the pDCs, specifically targeted using SiglecH-AFN. Later during disease progression, extra cDC1 targeting via Clec9A-AFN or XCL1-AFN adds to the protection. In addition, we found that targeting DCs increased the tolerogenic capacity (IL-10 and TGFβ production) of regulatory T and B lymphocytes. To get an idea about the convergence or redundancy of DC- and B cell targeting effects, we next compared monotherapies with combined therapies. Similar to shown in Fig. 1D, targeting B cells with CD20-AFN had a better efficacy than targeting DCs with either Clec9A-AFN or SiglecH-AFN. In addition, at a dose of 5000 IU, it was clear that while Clec9A-AFN cannot add to the CD20-AFN-mediated protection, SiglecH-AFN boosted the protec-
Lowering the treatment dose from 5000 to 1000 IU, the only significant protection obtained was when these monotherapies were combined (Fig. 3D–F).

Targeting B lymphocytes together with pDCs induces a superior systemic tolerogenic response. To ascertain tolerance against self, cell types such as tolDCs, Tregs and Bregs are essential. To get an idea about the mechanism(s) involved in EAE protection by combined pDC and B cell targeting, we decided to analyze these cells for their tolerogenic potential. Unfortunately, we could not analyze pDCs, which were undetectable via SiglecH-dependent flow cytometry analysis after 8 daily treatments with SiglecH-AFN, due to the endocytic nature of SiglecH which is very efficiently internalized after engagement24. When we analyzed B lymphocytes 2 h after the 8th AFN or PBS treatment (on day 15 after MOG inoculation), we found that the CD19+ B cell population was decreased during EAE, and this was not significantly affected by mono- or combined therapies (Fig. 4A). Interestingly, the fully protective CD20-AFN + SiglecH-AFN combination therapy was the only therapy that significantly increased both IL-10 (six-fold) and IDO expression (two-fold) in the general B cell population (Fig. 4B,C). While TGFβ-positive B cells were increased by all therapies, this was only significant for CD20-AFN (Fig. 4D). Several B cell subtypes have been implied as potentially regulatory or tolerogenic, and CD5+ CD1d+ B lymphocytes are often referred to as Bregs. Exacerbated EAE progression due to B cell depletion before disease initiation can be corrected by the adoptive transfer of spleen CD1dhi CD5+ Bregs, clearly demonstrating their tolerogenic efficacy25. Hence, we analyzed the numbers of CD5+ CD1d+ Bregs in spleens of EAE mice treated with AFNs, but could not find any significant differences in numbers (Fig. 4E). In terms of tolerogenic capacity, the Breg results were comparable to those obtained for the entire B cell population: significant increase was observed for IL-10 (4x) and IDO (2x) in mice that received the combination therapy (Fig. 4F,G), and for TGFβ in mice treated with CD20-AFN (Fig. 4H).
Figure 2. CD20-AFN protects better than Clec9A-AFN at lower doses, and in a therapeutic setting. Shown are clinical scores (A,B,D), % of diseased mice (C), body weight (E), or % of severely paralyzed mice (F). (A–C) Mice were treated with 1000 or 100 IU AFNs starting d7, (D–F) mice were treated with 5000 IU AFNs from d12 on. Shown are representative experiments (n = 5–7). The black horizontal arrow indicates the treatment period. Differences were assessed using two-way ANOVA followed by Dunnett's multiple-comparison test (A,B,D,E), or using Chi Square Log-Rank test for the Kaplan–Meier plots (C,F); *P < 0.05, **P < 0.01, compared with PBS treated animals.

Figure 3. CD20-AFN protects best in combination with SiglecH-AFN therapy. Shown are clinical scores (A,B,D,E), or % of severely paralyzed mice (C,F). (A–C) Mice were treated with 5000 IU AFNs starting d8, (D–F) mice were treated with 1000 IU AFNs from d8 on. Shown are 2 pooled experiments (n = 10–12). The black horizontal arrow indicates the treatment period, starting on d8. Differences were assessed using two-way ANOVA followed by Tukey’s multiple-comparison test (A,B,D,E), or using Chi Square Log-Rank test for the Kaplan–Meier plots (C,F); *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared with PBS treated animals, unless otherwise indicated (B).
Next we analyzed the T cell populations. In general, CD3+ T lymphocytes were significantly decreased due to EAE (Fig. 5A). While monotherapies slightly improved T cell numbers, only the combined CD20-AFN + SiglecH-AFN therapy completely restored T cell numbers. Within the general CD3+ T cell population, CD4+ CD25+ FoxP3+ Tregs were not increased (Fig. 5B), but when analyzed in the entire spleen cell population they were enhanced in case of combination therapy only (Fig. 5C). Tregs produced more IL-10 if treated with SiglecH-AFN (Fig. 5D), but no differences in IDO or TGFβ could be observed (Fig. 5E,F). Surprisingly, however, when analyzing the entire CD4+ and CD8+ T cell populations, we found that they displayed elevated IL-10 levels (Fig. 5G,J), and especially their IDO expression was very significantly affected by the combination therapy (Fig. 5H,K). For CD4+ T cells, this resulted in a two-fold increase (Fig. 5H), for CD8+ T cells even in a four-fold increase (Fig. 5K). There was no increase in TGFβ (Fig. 5L).

In our previous study, targeting DCS with SiglecH-AFN or Clec9A-AFN, we could not find any evidence at all of tolerization in conventional cDC1s on d12 (after 5 treatments) after MOG inoculation. In our current study, we analyzed DCS at a later time point and after 3 extra treatments (d15) and found evidence for a mild decrease in cDC1, but no changes in cDC2 (Fig. 6A,E). Interestingly, while monotherapies with either SiglecH-AFN or CD20-AFN could not significantly induce IL-10 or IDO in conventional DCS, the combined therapy resulted in dramatically enhanced levels (four- to five-fold increase) of IL-10 in both type 1 and type 2 DCS (Fig. 6B,F) and of IDO in cDC2s (Fig. 6G). IDO levels in cDC1s were not significantly increased after the combination therapy (Fig. 6C), and neither were TGFβ levels in cDC1s or cDC2s (Fig. 6D,H).

Discussion
In a previous study, we have demonstrated that targeting type I IFN activity specifically to DCS can protect against EAE onset and progression. To achieve this, we used Clec9A-AFN (targeting both pDCs and cDC1s) and SiglecH-AFN (targeting pDCs only); long-lasting protection was best when Clec9A-AFN was used, or when SiglecH-AFN treatment was supplemented with XCL1-AFN (targeting cDC1s only) later during disease. In the study reported here, we show that also targeting B cells with CD20-AFN is at least as protective as Clec9A-AFN, even when given after disease onset.

To evaluate the redundancy of DC and B cell targeting, we combined CD20-AFN with either Clec9A-AFN or SiglecH-AFN and found significant improvement of the therapy when B cell targeting was combined with pDC targeting. To understand the reason for this superior protection, we analyzed several cell types, including tolDCs, Tregs and Bregs, that have been implicated in inducing and maintaining tolerance against self. Mechanistically, cytokines such as IL-10 and TGFβ, as well as the induction of indoleamine 2,3-dioxygenase (IDO) activity, are known to be possibly involved in immunosuppression and tolerance. IL-10 is often referred to as the strongest immunosuppressive cytokine. Amongst others, it has a negative effect on APC and effector T cells, and a positive effect on regulatory T and B cells. In our previous study, we noted increased IL-10 production in Tregs and Bregs after 5 daily treatments with DC-targeted AFNs, but not in pDC or cDC1 populations. TGFβ is another important immunosuppressive cytokine, which we found increased in pDCs, Tregs and Bregs early (on d12, after 5 treatments) during DC-targeted therapy. IDO expression by APC is essential for fetal, oral, intestinal and...
Figure 5. Superior protective combination therapy correlates with IL-10 and IDO expression in T cells. Amounts of splenic T cells were decreased on d15 due to EAE, monotherapy AFNs did not affect that but the combination therapy did (A). The relative amounts of Tregs on all T cells were not changed (B), but in the whole spleen cell population significantly more Tregs were present in case of combination therapy (C). CD4+ CD25+ FoxP3+ Tregs produced more IL-10 if treated with SiglecH-AFN (D), but IDO and TGFβ expression were not affected (E,F). In all CD4+ T cells (G–I) IL-10 expression tended to be increased by all therapies, IDO expression was significantly enhanced only if EAE mice were treated with the combination therapy, while TGFβ levels were not altered. In CD8+ T cells (J–L) IL-10 and IDO expression were increased in case of combination therapy, TGFβ levels were not altered. Shown are 2 pooled experiments (n = 7). Differences were assessed using one-way ANOVA followed by Tukey’s multiple-comparison test; *P < 0.05, **P < 0.01, ***P < 0.001, compared with PBS treated animals, unless otherwise indicated.
resistance if they become IDO-positive\textsuperscript{33,34}. How exactly IDO expression in conventional DCs specifically needs targeting of AFN towards pDCs and B lymphocytes may have several explanations. Transcriptional regulation of IDO in myeloid cells is complex. For efficient long-lasting IDO induction and immune tolerance, the majority of data point to a “two-signal” requirement, with a powerful “signal one” required before “signal two” can impart full tryptophan catabolism\textsuperscript{26}. Potential triggers for IDO induction include Toll-like Receptor (TLR) ligands or IFNs as a “first signal”, aided by a “second signal” such as IL-10, TGF\(\beta\) or kynurenines that may be supplied in an autocrine or paracrine manner\textsuperscript{26,35,36}. In addition, in response to TGF\(\beta\) signaling, IDO has also been shown to act as an intracellular signal transducer necessary for the induction of a stable and long-term immune tolerance\textsuperscript{31,32}. Interestingly, type I IFN signaling in astrocytes can reduce EAE inflammation and disease scores via a mechanism involving tryptophan metabolites and AhR-dependent signaling\textsuperscript{37}. As such, one can imagine that endogenous type I IFN, which is known to be massively produced by pDCs, may contribute to AhR-dependent signaling and immunosuppression in the CNS (Fig. 7). In addition, we have previously shown increased TGF\(\beta\) and IDO, but not IL-10, in pDCs targeted with AFN\textsuperscript{18}. Hence, pDC-derived TGF\(\beta\), kynurenine and/or possibly also endogenous IFN, in combination with one or more endogenous B cell-derived signals such as IL-10\textsuperscript{38} or TGF\(\beta\)\textsuperscript{39}, may be responsible for the dramatically increased IDO levels we observed in both targeted (B lymphocytes) as well as non-targeted cell types (T lymphocytes and cDCs) during SiglecH-AFN + CD20-AFN combination therapy (Fig. 7). Furthermore, this “two-signal” requirement for stable IDO induction, with an immunogenic trigger such as TLR ligands or IFN constituting “signal one” and an immunosuppressive trigger such as IL-10, TGF\(\beta\) or kynurenine as “signal two”, may potentially provide an explanation for the long-term enigmatic paradox concerning the detrimental versus protective role of IFN\(\gamma\) in MS and EAE, as IFN\(\gamma\) may possibly have differential effects on different cell types (such as autoreactive T cells versus DCs) and/or in different disease stages\textsuperscript{39,40}.

In conclusion, we here demonstrate that, next to DC targeting, also specific B cell targeting with type I IFN activity can significantly prevent and delay EAE progression. Best protective effects were obtained when B cell targeting was combined with pDC targeting, using CD20-AFN plus SiglecH-AFN. This superior clinical effect was accompanied by enhanced IL-10 release in B cells and conventional DCs, and by the previously unseen induction of IDO in B lymphocytes, CD4\textsuperscript{+} and CD8\textsuperscript{+} T lymphocytes and cDC2s. Collectively, these data underscore the maximal tolerogenic potential of targeting type I IFN activity towards both pDCs and B lymphocytes, and indicate that the major molecular players are IDO and possibly IL-10.

Methods
EAE model and treatments. All animal experiments followed the Federation of European Laboratory Animal Science Association (FELASA) guidelines and were approved by the Ethical Committee of Ghent University. The EAE model was performed as previously described\textsuperscript{18}. Male 8 weeks old C57Bl/6j mice were immunized subcutaneously (s.c.) with 200 µg MOG35-55 in CFA containing 1 mg heat-killed Mycobacterium tuberculosis. Two hours and two days later 50 ng Pertussis Toxin was injected i.p. First signs of disease typically start on day 10–12. IFN or AFN intraperitoneal (i.p.) treatments were initiated on day 7 or 12 and lasted till day 23–25, depending on the experiment. Mice were weighed and scored daily. A score ranging from 0 to 2 indicates
progressive tail paralysis, with 1.5 for a partially limp tail (which is considered the onset of disease), and 2 for a completely limp tail. Score 2.5 is given if the animal no longer spreads its hind toes, score 3 for a waddled walk. Scores above 3 indicate increasing paralysis, with 3.5 for partial and 4 for complete hind limb paralysis. If forelimb paralysis is evident, score 5 is given and the animal is euthanized. Euthanasia was executed by CO2 inhalation by trained personnel using appropriate technique and equipment, death was confirmed by ascertaining respiratory and cardiac arrest. Treatment groups number 5–7 mice, experiments were repeated at least once. Differences were assessed using one-way or two-way ANOVA followed by Dunnett’s or Tukey’s multiple-comparison test. Survival curves were compared using the log-rank test. GraphPad Prism software was used for statistical analysis. All values depicted are mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 compared with PBS treated animals, unless otherwise indicated.

AcTaferons. We generated sdAbs selectively binding mouse CD20, Clec9A or SiglecH to use as targeting moieties. For the generation of AFNs, our lead IFNα mutant in mice is hIFNα2Q124R, a human IFNα2 mutant breaching the cross-species barrier and thus only very weakly active on murine cells (1/100 vs WT mIFNα). When fused to a targeting moiety that binds a cell-specific surface marker, AFNs regain full activity on the targeted cells by local avidity-driven receptor binding19. The generation and purification of AFNs was described before23,41.

Haematological and flow cytometry analysis. One day after the last treatment, blood was collected from the tail vein in EDTA-coated microvette tubes (Sarstedt), and analyzed in a Hemavet 950FS whole blood counter (Drew Scientific, Waterbury, USA). Spinal cord sections were dissected and stained with H&E, Luxol fast blue (LFB, for myelination assessment), and antibodies against amyloid precursor protein APP (evaluating respiratory and cardiac arrest). Treatment groups number 5–7 mice, experiments were repeated at least once. Differences were assessed using one-way or two-way ANOVA followed by Dunnett’s or Tukey’s multiple-comparison test. Survival curves were compared using the log-rank test. GraphPad Prism software was used for statistical analysis. All values depicted are mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 compared with PBS treated animals, unless otherwise indicated.

Ethical approval. All animal experiments followed the Federation of European Laboratory Animal Science Association guidelines and were approved by the Ethical Committee of the Faculty of Medicine, Ghent University, and carried out in compliance with the ARRIVE guidelines.
References

1. Baecher-Allan, C., Kaskow, B. J. & Weinr, H. L. Multiple sclerosis: Mechanisms and immunotherapy. Neuron 97, 742–768 (2018).

2. Rosati, G. The prevalence of multiple sclerosis in the world: An update. Neurol. Sci. 22, 117–139 (2001).

3. Urra, S. A., Antonelli, A., Sechi, G. M. & Group, M. S. W. Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey. Mult. Scler. 26, 372–380 (2020).

4. Tintore, M., Vidal-Jordana, A. & Sastre-Garriga, J. Treatment of multiple sclerosis—Success from bench to bedside. J. Neurol. Neurosurg. Psychiatry 85, 395–405 (2015).

5. Daclizumab withdrawn from the market worldwide.

6. Negron, A., Robinson, R. R., Stuve, O. & Forsthuber, T. G. The role of B cells in multiple sclerosis: Current and future therapies. Cell Immunol. 339, 10–23 (2019).

7. A. Ceronie, B. et al. Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. J. Neurol. 265, 1199–1209 (2018).

8. Baker, D., Marta, M., Pryce, G., Giovannoni, G. & Schmierer, K. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. Ebiomedicine 16, 41–50 (2017).

9. Rizzo, F. et al. Interferon-beta therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis. Immunol. Cell Biol. 94, 886–894 (2016).

10. Fucikova, J., Palova-Jelinkova, L., Bartunkova, J. & Spisek, R. Induction of tolerance and immunity by dendritic cells: Mechanisms and clinical applications. Front. Immunol. 10, 2393 (2019).

11. Mosanya, C. H. & Isaacs, J. D. Tolerising cellular therapies: What is their promise for autoimmune disease?. Ann. Rheum. Dis. 78, 297–310 (2019).

12. Cauwels, A. & Tavernier, J. Tolerizing strategies for the treatment of autoimmune diseases: From ex vivo to in vivo strategies. Front. Immunol. 11, 674 (2020).

13. Swager, U. & Rozman, P. Induction of tolerogenic dendritic cells by endogenous biomolecules: An update. Front. Immunol. 9, 2482 (2018).

14. Durelli, L. et al. Independent comparison of interferon trial study G: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359, 1453–1460 (2002).

15. Lugaresi, A. et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr. Dis. Treat. 9, 893–914 (2013).

16. Axtell, R. C. & Raman, C. Janus-like effects of type I interferon in autoimmune diseases. Immunol. Rev. 248, 23–35 (2012).

17. Verweij, C. L. & Vosselamber, S. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Dis. Curr. Med. 15, 51–60 (2013).

18. Cauwels, A. et al. Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice. J. Autoimmun. 97, 70–76 (2019).

19. Garcin, G. et al. High efficiency cell-specific targeting of cytokine activity. Nat. Commun. 5, 3016 (2014).

20. Schubert, R. D. et al. IFN-beta treatment requires B cells for efficacy in neuroautoimmunity. J. Immunol. 194, 2110–2116 (2015).

21. Robinson, A. P., Harp, C. T., Noronha, A. & Miller, S. D. The experimental autoimmune encephalomyelitis (EAE) model of MS: Utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 122, 173–189 (2014).

22. Blasius, A. L. & Colonna, M. Sampling and signaling in plasmacytoid dendritic cells: The potential roles of Siglec-H. Trends Immunol. 27, 255–260 (2006).

23. Cauwels, A. et al. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncocemunology 7, e1398678 (2018).

24. Zhang, J. et al. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107, 3600–3608 (2006).

25. Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M. & Tedder, T. F. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Investig. 118, 3420–3430 (2008).

26. Harden, J. L. & Eglmez, N. K. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol. Investig. 41, 738–764 (2012).

27. Bettioli, E. et al. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol. 161, 3299–3306 (1998).

28. Yan, Y. et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J. Immunol. 185, 3593–3591 (2010).

29. Lippens, C. et al. IDO-orchestrated crosstalk between pDCs and Tregs inhibits autoimmunity. J. Autoimmun. 75, 39–49 (2016).

30. Wu, H., Gong, J. & Liu, Y. Indoleamine 2,3-dioxygenase regulation of immune response (review). Mol. Med. Rep. 17, 4867–4873 (2018).

31. Chen, W. IDO: More than an enzyme. Nat. Immunol. 12, 809–811 (2011).

32. Pallotta, M. T. et al. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat. Immunol. 12, 870–878 (2011).

33. Luka, D. et al. TGF-beta inhibitor Smad7 regulates dendritic cell-induced autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 114, E1480–E1489 (2017).

34. Matysiak, M. et al. Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism. J. Neuroimmunol. 193, 12–23 (2008).

35. Munn, D. H. & Mellor, A. L. Indoleamine 2,3-dioxygenase and metabolic control of immune responses. Trends Immunol. 34, 137–143 (2013).

36. Rosati, G. The prevalence of multiple sclerosis in the world: An update. Neurol. Sci. 22, 117–139 (2001).

37. Li, Q., Harden, J. L., Anderson, C. D. & Eglmez, N. K. Tolerogenic phenotype of IFN-gamma-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop. J. Immunol. 197, 962–970 (2016).

38. Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586–597 (2016).

39. Yanagawa, Y., Iwabuchi, K. & Onoe, K. Co-operative action of interleukin-10 and interferon-gamma to regulate dendritic cell FAS-mediated apoptosis. Immunol. Investig. 127, 345–359 (2009).

40. Ottum, P. A., Arelanno, G., Reyes, L. I., Burgos, P. I. & Naves, R. Stage-specific role of interferon-gamma in experimental autoimmune encephalomyelitis and multiple sclerosis. Front. Immunol. 6, 492 (2015).

41. Ottum, P. A., Arelanno, G., Reyes, L. I., Irurtagoyena, M. & Naves, R. Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front. Immunol. 6, 539 (2015).
41. Cauwels, A. et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. 
Cancer Res. 78, 463–474 (2018).

Acknowledgements
We thank Reza Hassanzadeh Ghassabeh (VIB Nanobody Core) for the selection of the sdAbs. This work was supported by the Charcot Foundation, UGent Methusalem and Advanced ERC (CYRE, Nº 340941), and by Orionis Biosciences.

Author contributions
A.C. and J.T. conceived and designed the research and wrote the manuscript. A.C. conducted and analyzed the mouse experiments and data. S.L. performed flow cytometry and FlowJo analysis. E.R., A.V. and B.E. provided technical support, including constructions, purifications and help with animal work and flow cytometry analyses. S.P. and M.P. analyzed spinal cords. N.K. and G.U. contributed to the manuscript.

Competing interests
AC, ER, NK and JT are affiliated with Orionis Biosciences; NK and JT also hold equity interests in Orionis Bioscience; JT received financial research support from Orionis Biosciences NV. All the other authors declare no conflict of interest.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-00891-6.

Correspondence and requests for materials should be addressed to A.C. or J.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021